

7 October 2021

## **Access to PET-CT for Prostate Cancer**

**1. Does your trust/ HB have access to PET-CT for the investigation of suspected biochemical recurrence in prostate cancer patients?**

No

**2. If you answered “No” to question 1. Would you use PET-CT for the investigation of suspected biochemical recurrence in prostate cancer patients if it were available?**

Yes

**3. In 2020-21, how many patients do you estimate were investigated for suspected biochemical recurrence of prostate cancer at your trust/HB?**

50-60 (Central prostate clinic)

**4. What percentage of patients with suspected biochemical recurrence do you estimate are referred for PET-CT at your trust/HB?**

<1% (others need to self-fund to travel to London Privately)

**5. Of patients with suspected biochemical recurrence referred for PET-CT, what % of scans do you estimate use a PSMA tracer (either Ga-PSMA or F-PSMA)?**

100%

**6. Are there any exclusion criteria for referral for PET-CT for suspected biochemical recurrence of prostate cancer? If so, what are they? E.g. Upper and lower PSA limits, age, life expectancy, ECOG score.**

PSA >0.2 no upper limit when conventional imaging negative

**7. What do you estimate is the average waiting time for the PET-CT scans for investigation of suspected biochemical recurrence of prostate cancer?**

Only use private sector in London (self-pay- therefore no waiting list)

**8. What do you estimate is the average time it takes to report PET-CT scans for investigation of suspected biochemical recurrence of prostate cancer?**

1 day